Enrolling by invitationPhase 2NCT06971900
GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria
Studying Disorder of porphyrin and heme metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Portal Therapeutics, Inc.
- Principal Investigator
- Chief Medical OfficerPortal Therapeutics, Inc.
- Intervention
- PORT-77(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Celerion, Tempe, Arizona, United States
Collaborators
Celerion
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06971900 on ClinicalTrials.govOther trials for Disorder of porphyrin and heme metabolism
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06910358Study of Bitopertin in Participants With EPP or XLP (APOLLO)Disc Medicine, Inc
- ACTIVE NOT RECRUITINGNCT02935400Acute Porphyria Biomarkers for Disease ActivityThe University of Texas Medical Branch, Galveston
- ACTIVE NOT RECRUITINGNCT01617642Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)Nordlandssykehuset HF
See all trials for Disorder of porphyrin and heme metabolism →